A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effects of ALKS 4230 monotherapy on
the tumor microenvironment of a variety of advanced, malignant solid tumors.